K. Shetty

1,3-Dipolar cycloaddition of C-aryl-N-phenylnitrones to (R)-1-(1-phenylethyl)-3-[(E)-arylmethylidene]tetrahydro-4(1H)-pyridinones: synthesis and antimycobacterial evaluation of enantiomerically pure spiroisoxazolidines.

P. Yogeeswari, D. Sriram, Raju Suresh Kumar, 2010, European journal of medicinal chemistry.

Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.

D. Mager, S. Balu-Iyer, M. Kosloski, 2015, Journal of pharmaceutical sciences.

Effects of Replacement of Factor VIII Amino Acids Asp519 and Glu665 with Val on Plasma Survival and Efficacy In Vivo

S. Balu-Iyer, P. Fay, H. Wakabayashi, 2014, AAPS Journal.

Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti‐factor VIII antibodies in hemophilia A mice

D. Mager, S. Balu-Iyer, M. Kosloski, 2016, Biopharmaceutics & drug disposition.

Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs.

T. Nichols, E. Merricks, S. Balu-Iyer, 2016, Journal of pharmaceutical sciences.

Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism Soy PhosphatidylinositoleContaining Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domaineDeleted Recombinant Canine Factor VIII in Hemophilia A Dogs

T. Nichols, E. Merricks, S. Balu-Iyer, 2016 .

A microwave-assisted facile regioselective Fischer indole synthesis and antitubercular evaluation of novel 2-aryl-3,4-dihydro-2H-thieno[3,2-b]indoles.

P. Yogeeswari, D. Sriram, S. Karthikeyan, 2009, Bioorganic & medicinal chemistry letters.

1,3-Dipolar cycloaddition of C-aryl-N-phenylnitrones to (R)-1-(1-phenylethyl)-3-[(E)-arylmethylidene]tetrahydro-4(1H)-pyridinones: synthesis and antimycobacterial evaluation of enantiomerically pure spiroisoxazolidines.

P. Yogeeswari, D. Sriram, Raju Suresh Kumar, 2010, European journal of medicinal chemistry.

FDA Approval Summary: Margetuximab plus chemotherapy for advanced or metastatic HER2-positive breast cancer.

R. Pazdur, R. Charlab, B. King-Kallimanis, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.